Abstract
Cancer, once considered as an incurable disease, today, becomes not that difficult to be treated due to the newly emerging nanotechnology and the rapid development of “smart” drug delivery systems. New cancer therapeutics ought to overcome the defects of conventional drug delivery systems, such as nonspecific bio-distribution or targeting, short circulation time, etc. Tumor targeted drug delivery systems basically includes two strategies: passive and active targeting. Passive targeting is often referred to the enhanced permeability and retention effect (EPR effect) due to the enhanced vascular penetration of tumor capillaries and limited lymphatic drainage of lymphatic capillaries. Active targeting systems are based on local stimuli characteristic of the target pathological zone (such as, increased temperature or lowered pH values, redox potential changes, characteristic of inflamed, the receptor mediated internalization by target cells, etc.). Intriguingly, the combination of the two strategies above is promising and exciting. Herein, we give a brief review of tumor targeted drug delivery systems based on tumor cell itself and its external milieu.
Keywords: Drug delivery systems, smart nanocarriers, tumor targeting, Carcinoma, conventional therapeutics, blood circulation, ENDOCYTOSIS, NANOMEDICINES, PASSIVE TARGETING
Drug Delivery Letters
Title: “Smart” Nanocarriers: A New Paradigm for Tumor Targeting Drug Delivery Systems
Volume: 1 Issue: 1
Author(s): Zhigang Hu, Fei Huo, Yi Zhang, Chunyang Chen, Kehua Tu, Hongliang Jiang and Li-Qun Wang
Affiliation:
Keywords: Drug delivery systems, smart nanocarriers, tumor targeting, Carcinoma, conventional therapeutics, blood circulation, ENDOCYTOSIS, NANOMEDICINES, PASSIVE TARGETING
Abstract: Cancer, once considered as an incurable disease, today, becomes not that difficult to be treated due to the newly emerging nanotechnology and the rapid development of “smart” drug delivery systems. New cancer therapeutics ought to overcome the defects of conventional drug delivery systems, such as nonspecific bio-distribution or targeting, short circulation time, etc. Tumor targeted drug delivery systems basically includes two strategies: passive and active targeting. Passive targeting is often referred to the enhanced permeability and retention effect (EPR effect) due to the enhanced vascular penetration of tumor capillaries and limited lymphatic drainage of lymphatic capillaries. Active targeting systems are based on local stimuli characteristic of the target pathological zone (such as, increased temperature or lowered pH values, redox potential changes, characteristic of inflamed, the receptor mediated internalization by target cells, etc.). Intriguingly, the combination of the two strategies above is promising and exciting. Herein, we give a brief review of tumor targeted drug delivery systems based on tumor cell itself and its external milieu.
Export Options
About this article
Cite this article as:
Hu Zhigang, Huo Fei, Zhang Yi, Chen Chunyang, Tu Kehua, Jiang Hongliang and Wang Li-Qun, “Smart” Nanocarriers: A New Paradigm for Tumor Targeting Drug Delivery Systems, Drug Delivery Letters 2011; 1 (1) . https://dx.doi.org/10.2174/2210304x11101010067
DOI https://dx.doi.org/10.2174/2210304x11101010067 |
Print ISSN 2210-3031 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-304X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Improved Drug Delivery Technologies for Pentacyclic Triterpenes: A Review
Protein & Peptide Letters Hepatocyte Growth Factor Signaling in Cancer Metastasis
Current Signal Transduction Therapy Butyrate and Colorectal Cancer: The Role of Butyrate Transport
Current Drug Metabolism Targeting Ovarian Cancer-Initiating Cells
Anti-Cancer Agents in Medicinal Chemistry Effect of miR-128 in DNA Damage of HL-60 Acute Myeloid Leukemia Cells
Current Pharmaceutical Biotechnology Assessing Combinations of Cytotoxic Agents Using Leukemia Cell Lines
Current Drug Targets The Role of the Anti-Amyloidogenic Secretase ADAM10 in Shedding the APP-like Proteins
Current Alzheimer Research bHLH Transcription Factors Inhibitors for Cancer Therapy: General Features for In Silico Drug Design
Current Medicinal Chemistry Phytochemicals: Potential in Management of Climacteric Neurobiology
Current Pharmaceutical Design Multi-targeting the Entrance Door to Block HIV-1
Current Drug Targets - Infectious Disorders NGR-based Strategies for Targeting Delivery of Chemotherapeutics to Tumor Vasculature
Anti-Cancer Agents in Medicinal Chemistry Targeting Focal Adhesion Kinase in Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry Lentiviral Vectors: A Versatile Tool to Fight Cancer
Current Molecular Medicine Functionalized Carbon Nano-scale Drug Delivery Systems From Biowaste Sago Bark For Cancer Cell Imaging
Current Drug Delivery Status of Flavonols as P-Glycoprotein Inhibitors in Cancer Chemotherapy
Current Cancer Therapy Reviews Metal Containing Cytostatics and Their Interaction with Cellular Thiol Compounds Causing Chemoresistance
Anti-Cancer Agents in Medicinal Chemistry Nephrotoxicity of Bisphenol A (BPA) -An Updated Review
Current Molecular Pharmacology Genetic Engineering of AAV Capsid Gene for Gene Therapy Application
Current Gene Therapy Glutamate mGlu5-Adenosine A2A-Dopamine D2 Receptor Interactions in the Striatum. Implications for Drug Therapy in Neuro-psychiatric Disorders and Drug Abuse
Current Medicinal Chemistry - Central Nervous System Agents Binding Sites of Amyloid β-Peptide in Cell Plasma Membrane and Implications for Alzheimers Disease
Current Protein & Peptide Science